search
Back to results

The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.

Primary Purpose

Dementia With Vitamin B12 Deficiency

Status
Completed
Phase
Phase 4
Locations
China
Study Type
Interventional
Intervention
Mecobalamin
Sponsored by
Eisai Co., Ltd.
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Dementia With Vitamin B12 Deficiency

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All Sexes

Inclusion: Patients with Dementia Serum B12 < 200 pmol/l Serum Homocysteine level > 11.0 micro mol/L Exclusion: Significant communication problems deafness, dysarthria, dysphasia etc. unstable DM or hypertension alcohol abuse co-existing diseases which may affect cognition e.g. cognitive cardiac failure, respiratory failure folate < 10 g/dl haemoglobin concentration < 10g/d abnormal thyroid function test or VDRL

Sites / Locations

  • Chinese University of Hong Kong

Outcomes

Primary Outcome Measures

Mattis dementia rating scale

Secondary Outcome Measures

Category fluency test
Delirium rating scale
CNPI
MMSE
Plasma homocysteine
Plasma isoprostane

Full Information

First Posted
September 12, 2005
Last Updated
February 18, 2019
Sponsor
Eisai Co., Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT00165711
Brief Title
The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.
Study Type
Interventional

2. Study Status

Record Verification Date
December 2005
Overall Recruitment Status
Completed
Study Start Date
March 2003 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Eisai Co., Ltd.

4. Oversight

5. Study Description

Brief Summary
Patients who fit the inclusion criteria are admitted into the study. They are given 3 IV injection of MBL in the first week and one tablet three times a day for 16 weeks.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Dementia With Vitamin B12 Deficiency

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Mecobalamin
Primary Outcome Measure Information:
Title
Mattis dementia rating scale
Secondary Outcome Measure Information:
Title
Category fluency test
Title
Delirium rating scale
Title
CNPI
Title
MMSE
Title
Plasma homocysteine
Title
Plasma isoprostane

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Eligibility Criteria
Inclusion: Patients with Dementia Serum B12 < 200 pmol/l Serum Homocysteine level > 11.0 micro mol/L Exclusion: Significant communication problems deafness, dysarthria, dysphasia etc. unstable DM or hypertension alcohol abuse co-existing diseases which may affect cognition e.g. cognitive cardiac failure, respiratory failure folate < 10 g/dl haemoglobin concentration < 10g/d abnormal thyroid function test or VDRL
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Romeo Chu
Organizational Affiliation
Eisai Asia Regional Services Ltd.
Official's Role
Study Director
Facility Information:
Facility Name
Chinese University of Hong Kong
City
Hong Kong
State/Province
Hong Kong
Country
China

12. IPD Sharing Statement

Learn more about this trial

The Role of Methycobalamin in Early Dementia Patients With Vitamin B12 Deficiency and Hyperhomocysteinaemia.

We'll reach out to this number within 24 hrs